Vimarsana
Biggest News Aggregation in the World

Clinical Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Response Today - Breaking & Trending Today

5 important questions to ask your doctor before considering Bariatric Surgery for weight loss - Vimarsana News

5 important questions to ask your doctor before considering Bariatric Surgery for weight loss

Before deciding to proceed with weight loss surgery or Bariatric Surgery, here are a few things that patients should discuss with their doctor | Health

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024 - Vimarsana News

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Results Reveal Mechanism of Action and Correlative Analyses DataHELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024. TILT-123 in combination with MS

Source: yahoo.com
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma - Vimarsana News

TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...

Elements of religiosity and spirituality help predict clinical response to treatment in adults with mild-to-moderate depression - Vimarsana News

Elements of religiosity and spirituality help predict clinical response to treatment in adults with mild-to-moderate depression

1. In this randomized controlled trial, depressed patients who received Meditation-Based Lifestyle Modification (MBLM) had a greater increase in spirituality than those who received treatment as usual. 2. Furthermore, baseline interest in spirituality and engagement in mind-body practice were two predictive factors of improved depression and perceived stress in response to treatment. Evidence Rating Level:

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - Vimarsana News

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response in r/r Peripheral T-cell Lymphomas ; ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient...